Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $19.60.

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Wednesday, November 19th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TARA. Police & Firemen s Retirement System of New Jersey purchased a new stake in Protara Therapeutics in the 2nd quarter worth about $30,000. Quadrature Capital Ltd acquired a new position in shares of Protara Therapeutics in the 2nd quarter valued at about $35,000. Almanack Investment Partners LLC. purchased a new stake in shares of Protara Therapeutics in the third quarter worth approximately $59,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Protara Therapeutics during the first quarter worth approximately $64,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Protara Therapeutics during the second quarter worth approximately $46,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Stock Down 2.0%

Shares of Protara Therapeutics stock opened at $7.41 on Thursday. Protara Therapeutics has a 12-month low of $2.48 and a 12-month high of $10.48. The firm has a market capitalization of $285.93 million, a PE ratio of -4.57 and a beta of 1.59. The stock’s fifty day moving average is $5.16 and its 200-day moving average is $3.84.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. Analysts expect that Protara Therapeutics will post -3.32 EPS for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.